JNJ-70033093 clinical trials

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

This study is testing a new medicine called Milvexian for people who have recently had a heart attack or similar heart problem. We want to see if it can prevent future serious heart issues better than existing treatments, with fewer side effects.